Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Ann Surg. 2018 May;267(5):797–805. doi: 10.1097/SLA.0000000000002574

Figure 2.

Figure 2

(A) Comparing all patients with pathologically-confirmed H-CCA who underwent curative-intent transplant (n=41) to those who underwent curative-intent resection (n=191). The median survival was not reached (MNR) among transplant patients, and 1-, 3-, and 5-year survivals were 93%, 72%, and 64%, respectively. The median survival among resection patients was 21.0 months (95% CI, 16.5–25.5), and 1-, 3-, and 5-year survivals were 71%, 33%, and 18%, respectively (log rank p<0.001). (B) Comparing all patients with pathologically-confirmed H-CCA who underwent curative-intent transplant to those who underwent curative-intent resection and had tumors <3cm in size and no lymph node disease (N0) on pathologic examination (n=57). The median survival for this subset of resection patients was 27.4 months (95% CI, 6.0–48.8), and 1-, 3-, and 5-year survivals were 72%, 45%, and 31%, respectively (log rank p<0.001).